Royalty Pharma Plc (RPRX) Stock Analysis

Royalty Pharma Plc (RPRX) is a publicly traded company in the HEALTHCARE sector. It trades at $54.01, carries a market capitalization of $31.77B, a price-to-earnings ratio of 29.04, a dividend yield of 0.02%. This page summarizes the public market data, fundamentals, and frequently asked questions for RPRX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Royalty Pharma Plc currently has a Bearish sentiment score of -0.22.

About Royalty Pharma Plc

Royalty Pharma plc, based in New York, is a premier acquirer of biopharmaceutical royalties and a key player in funding innovative therapies within the industry. The company specializes in acquiring royalties from both established and emerging drug portfolios, thereby providing essential capital for ongoing research and development efforts. With its strategic approach to optimizing royalty streams, Royalty Pharma is poised to leverage the expansion of the biopharmaceutical sector, presenting ...

GNG Research Analysis

GNG Research scores Royalty Pharma Plc (RPRX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RPRX.

Frequently Asked Questions

What is RPRX's current dividend yield?

Royalty Pharma Plc (RPRX) has a current dividend yield of 0.02%.

Does RPRX pay dividends?

Yes, Royalty Pharma Plc pays dividends with a current yield of 0.02%.

What is RPRX's P/E ratio?

Royalty Pharma Plc has a price-to-earnings (P/E) ratio of 29.04.

What is RPRX's market cap?

Royalty Pharma Plc (RPRX) has a market capitalization of $31.77B with a current stock price of $54.01.